

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-12. (Canceled)

13. (Currently Amended) A method of inhibiting ~~lymphocyte activation~~ **the activity of activated lymphocytes**, comprising administering to a patient in need thereof an antibody that binds to a protein having an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 1, **wherein said antibody is produced by hybridoma FERM BP-5233 and, wherein the lymphocytes are B cells.**

14-19. (Canceled)

20. (Currently Amended) ~~A~~ **The** method according to claim ~~18~~ **13**, wherein the antibody binds to an epitope recognized by an anti-HM1.24 antibody.

21-22. (Canceled)

23. (Currently Amended) A method of treating a disease associated with lymphocyte activation, comprising administering to a patient in need thereof an antibody that binds to a protein having an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 1, **wherein said antibody is produced by hybridoma FERM BP-5233 and, wherein the lymphocytes are B cells.**

24. (Currently Amended) ~~A~~ **The** method according to claim 23, wherein said disease is selected from the group consisting of autoimmune disease, rejection in organ transplantation, and allergy.

25. (New) A method of inhibiting the activity of activated lymphocytes, comprising administering to a patient in need thereof an antibody that binds to a protein having an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 1, wherein the antibody has an L chain V region of SEQ ID NO:2, and an H chain V region selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.

26. (New) The method according to claim 25, wherein the antibody is a monoclonal antibody.

27. (New) The method according to claim 26, wherein the antibody comprises a constant region of human antibody.

28. (New) The method according to claim 26, wherein the antibody is a chimeric antibody.

29. (New) The method according to claim 26, wherein the antibody is a humanized antibody.

30. (New) The method according to claim 25, wherein the antibody binds to an epitope recognized by an anti-HM1.24 antibody.

31. (New) A method of treating a disease associated with lymphocyte activation, comprising administering to a patient in need thereof an antibody that binds to a protein having an amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 1, wherein the antibody has an L chain V region of SEQ ID NO:2, and an H chain V region selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:4.

32. (New) The method according to claim 31, wherein said disease is selected from the group consisting of autoimmune disease, rejection in organ transplantation, and allergy.